Atomic spectrometry and trends in clinical laboratory medicine

被引:118
作者
Parsons, Patrick J.
Barbosa, Fernando, Jr.
机构
[1] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA
[2] SUNY Albany, Sch Publ Hlth, Dept Environm Hlth Sci, Albany, NY 12201 USA
[3] Fac Ciencias Farmaceut, Dept Analises Clin Toxicol & Bromatol, BR-14040 Ribeirao Preto, Brazil
关键词
atomic spectrometry; clinical laboratory medicine; AAS; ICP-MS; speciation;
D O I
10.1016/j.sab.2007.03.007
中图分类号
O433 [光谱学];
学科分类号
0703 ; 070302 ;
摘要
Increasing numbers of clinical laboratories are transitioning away from flame and electrothermal AAS methods to those based on ICP-MS. Still, for manv laboratories, the choice of instrumentation is based upon (a) the element(s) to be determined, (b) the matrix/matrices to be analyzed, and (c) the expected concentration(s) of the analytes in the matrix. Most clinical laboratories specialize in measuring Se, Zn, Cu, and At in serum, and/or Pb. Cd. Hg, As, and Cr in blood and/or urine, while other trace elements (e.g., Pt, An etc.) are measured for therapeutic purposes. Quantitative measurement of elemental species is becoming more widely accepted for nutritional and/or toxicological screening purposes, and ICP-MS interfaced with separation techniques, such as liquid chromatography or capillary electrophoresis, offers the advantage of on-line species determination coupled with very low detection limits. Polyatomic interferences for some key elements such as Se, As, and Cr require instrumentation equipped with dynamic reaction cell or collision cell technologies, or might even necessitate the use of sector field TCP-MS, to assure accurate results. Nonetheless, whatever analytical method is selected for the task, careful consideration must be given both to specimen collection procedures and to the control of pre-analytical variables. Finally, all methods benefit from access to reliable certified reference materials (CRMs). While a variety of reference materials (RMs) are available for trace element measurements in clinical matrices, not all can be classified as CRMs. The major metrological organizations (e.g., NIST, IRMM, NIES) provide a limited number of clinical CRMs, however, secondary reference materials are readily available from commercial organizations and organizers of external quality assessment schemes. (C) 2007 Published by Elsevier B.V.
引用
收藏
页码:992 / 1003
页数:12
相关论文
共 64 条
[1]  
Albalak R, 2005, ATOM SPECTROSC, V26, P234
[2]   A critical review of biomarkers used for monitoring human exposure to lead: Advantages, limitations, and future needs [J].
Barbosa, F ;
Tanus-Santos, JE ;
Gerlach, RF ;
Parsons, PJ .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2005, 113 (12) :1669-1674
[3]   Evaluation of the use of salivary lead levels as a surrogate of blood lead or plasma lead levels in lead exposed subjects [J].
Barbosa, Fernando, Jr. ;
Heloisa, Maria ;
Rodrigues, Correa ;
Buzalaf, Maria R. ;
Krug, Francisco J. ;
Gerlach, Raquel F. ;
Tanus-Santos, Jose Eduardo .
ARCHIVES OF TOXICOLOGY, 2006, 80 (10) :633-637
[4]   Contrasting effects of age on the plasma/whole blood lead ratio in men and women with a history of lead exposure [J].
Barbosa, Fernando, Jr. ;
Ramires, Irene ;
Rodrigues, Maria Heloisa C. ;
Saint' Pierre, Tatiana D. ;
Curtius, Adilson J. ;
Buzalaf, Marilia R. ;
Gerlach, Raquel F. ;
Tanus-Santos, Jose E. .
ENVIRONMENTAL RESEARCH, 2006, 102 (01) :90-95
[5]   Methylmercury measurement in whole blood by isotope-dilution GC-ICPMS with 2 sample preparation methods [J].
Baxter, Douglas C. ;
Rodushkin, Ilia ;
Engstrom, Emma ;
Klockare, Dennis ;
Waara, Hans .
CLINICAL CHEMISTRY, 2007, 53 (01) :111-116
[6]  
Caldwell KL, 2005, ATOM SPECTROSC, V26, P1
[7]   Use of inductively coupled plasma mass spectrometry to measure urinary iodine in NHANES 2000: Comparison with previous method [J].
Caldwell, KL ;
Maxwell, CB ;
Makhmudov, A ;
Pino, S ;
Braverman, LE ;
Jones, RL ;
Hollowell, JG .
CLINICAL CHEMISTRY, 2003, 49 (06) :1019-1021
[8]  
CALI JP, 1978, NBS SPEC PUBL, V260, P1
[9]  
*CDC, 2006, NAT REP HUM ENV CHEM
[10]  
CDC, 2005, 3 NAT REP HUM EXP EN, P1